Danger signals in stroke and their role on microglia activation after ischemia

Eileen Gülke, Mathias Gelderblom and Tim Magnus

Abstract: Ischemic stroke is a major cause of death. Besides the direct damage resulting from oxygen and glucose deprivation, sterile inflammation plays a pivotal role in increasing cellular death. Damaged-associated molecular patterns (DAMPs) are passively released from dying cells and activate the innate immune system. Thus, they take part in the direct and rapid activation of the inflammatory response after stroke onset. In this review the role of the most important DAMPs, high mobility group box 1, heat and cold shock proteins, purines, and peroxiredoxins, are addressed. Moreover, intracellular pathways activated by DAMPs in microglia are illuminated.

Keywords: DAMPs, stroke, microglia, HMGB1, purines, Hsp, peroxiredoxin

Introduction

Stroke is a major issue in terms of an increasing incidence and considering disability-adjusted life years (DALYs) lost. In 2030 up to 12 million deaths are expected. Moreover, it is the leading cause of long-term disability. Approximately 2 million neurons per minute die when exposed to ischemia. Acute thromboembolic or local thrombotic occlusion of a cerebral artery accounts for 80% of strokes. Systemic thrombolysis and mechanic recanalization are so far the only acute treatments in these cases, but less than 20% of patients receive it due to restrictive inclusion criteria. Besides the direct brain injury resulting from ischemia and reperfusion, there is growing evidence that a rapid evolving sterile inflammation worsens infarct size in the first 1–3 days post stroke, and thus clinical outcome. In immune-deficient mice, about 20–30% smaller infarct sizes were detected after experimental stroke induction. Cells invade the ischemic brain in a specific temporal and spatial pattern. In the first couple of days, neutrophils, macrophages and microglia predominantly infiltrate the ischemic tissue in large numbers, reaching their maximum around 3 days post ischemia. Even though smaller in numbers, other potentially highly immune competent lymphocyte subpopulations and dendritic cells accumulate in the ischemic tissue during the first days after the ischemic insult. Overall, the initial cellular inflammatory reaction follows a highly conserved pattern of sterile inflammatory reactions, which are also known from other organs. Whereas the detrimental effects of proinflammatory signals released by the innate immune system occur in the early course of stroke, the role of the adaptive immune system is still controversial. Interestingly, the immunologic response not only accounts for detrimental effects, but it also influences neuronal regeneration in the following weeks and months after brain infarction. In the setting of infections by pathogens, the immune system protects the human body against danger in general, as introduced by Polly Matzinger in 1994. These warning mechanisms are not only released by pathogens, they also encompass released or secreted molecules from injured cells, which are called damaged-associated molecular patterns (DAMPs). In general, DAMPs can be divided into PAMPs (pathogen-associated molecular patterns) and alarmins, which categorize endogenous molecules. Both protein [e.g. high mobility group box 1 (HMGB1), heat shock proteins (Hsps)] and nonprotein alarmins (e.g. adenosine triphosphate (ATP)) exist. Overall, DAMPs are promising candidates in stroke pathophysiology as several experimental data indicate their importance for the activation of the immune system early following ischemia. In stroke, the sterile inflammation starts with the release of DAMPs from dying neuronal and non-neuronal brain cells, which then activate local immune cells (e.g. microglia) and perivascular...
endothelia cells via pattern recognition receptors (PRRs) including toll-like receptors (TLRs). The local immune reaction is amplified, which results in the massive invasion of systemic immune cells.3 Besides the local immune response, activation of the immune system also has systemic consequences, since the phenomenon of a systemic immune suppression can be observed in stroke patients. This is associated with an increased susceptibility to bacterial infections such as pneumonia or lower urinary infections.12 As depicted, the inflammatory response is a major potential target of future therapeutic treatments in stroke. In this review, we focus on the acute involvement of DAMPs as one of the first reactions after ischemia.

**High mobility group box 1**

The HMGB1 protein is a widely expressed non-histone cytokine-like factor, which mainly stabilizes the chromosomes in the nucleus.13 Under physiological conditions, it has a proangiogenic effect on endothelial cells and neurite outgrowth is stimulated by HMGB1 during embryogenesis.14 HMGB1 is both passively released from necrotic cells and actively secreted by the innate immune system in case of infections. Interestingly, it does not diffuse in the extracellular matrix when cells undergo apoptosis because here HMGB1 binds irreversibly to the modified chromatin.15,16 HMGB1 appears early in sterile inflammation and initiates the production of proinflammatory mediators.14,17 Multiple extracellular receptors are activated by HMGB1, including the receptor for advanced glycation end products (RAGE) or TLR2 and TLR4, which are ubiquitously expressed by resident central nervous system (CNS) cells.18 Additionally, HMGB1 possesses divergent functions in different redox states.19 In positions 23, 45 and 106, three cysteine residues are located. A disulfide bond between C23 and C45 as well as the thiol form of C106 is obligatory for its tumor necrosis factor (TNF)-stimulating effects via TLR4.20,21 Overall, the reduced form is associated with chemotactic functions whereas the disulfide form is thought to be proinflammatory through the induction of nucleotide-binding domain, leucine-rich repeat, pyrin domain containing protein 3 (NLRP3) and nuclear factor κB (NFκB).22

HMGB1 also plays a pivotal role in ischemic stroke. High levels of systemic HGMB1 were measured in serums of patients with cerebral ischemia.23 Elevated HMGB1 levels correlate with severe stroke sizes.24–26 In the CNS, HMGB1 is upregulated after stroke and maintains the inflammatory process.27 It is secreted by activated astrocytes and microglia, and stimulates the release of interleukin (IL)-1, TNFα, IL-6 and IL-8, as well as inducible nitric oxide synthase (iNOS) expression.28–31 An increased vascular and blood–brain barrier permeability is observed.31 Moreover, matrix metalloproteinase 9 (MMP-9) is upregulated by HMGB1 via TLR4 and its induced cytokines as TNFα or IL-1β mediating cellular death after ischemic stroke.31 A maturation process of the passively released protein in the blood circulation to a cytokine-stimulating isoform has been described.32 Furthermore, HGMB1-induced activation of RAGE results in systemic lymphocytopenia after brain ischemia.32 Locally, the amplification of the post-ischemic inflammation is also maintained by HMGB1.33,34 Leucocyte infiltration is stimulated as well as activation of microglia and amplification of metalloproteinases. The late treatment with amlexanox or an anti-HMGB1 antibody after ischemia appears to protect the brain from stroke-induced brain damage by the inhibition of the release of HMGB1.35 Several studies demonstrated protective effects by pharmacological inhibition of HMGB1 or its pathway underlying the detrimental function of HMGB1 in the early stages following stroke.3,36–38 Reduced inflammation and stroke size are seen after inhibition of RAGE or TLR4.34,39 Contrary to that, HMGB1 also stimulates angiogenesis, neurite outgrowth and neuronal survival in the late period after stroke, and is actively secreted by astrocytes with positive signaling on endothelial progenitor cells.31 In summary, HMGB1 has mainly detrimental effects in the early post-ischemic period, though HMGB1 activation also occurs to take part in stroke recovery mechanisms.

**Heat shock proteins and cold shock domain proteins**

Hsps belong to the group of molecular chaperones, which help guide the correct folding of proteins during their synthesis. They are produced when cells are exposed to elevated temperatures or any kind of injury as part of a feedback system, which detects misfolded proteins.40 The two major chaperones are Hsp60 and Hsp70, which are located in the cytosol. Hsp70 acts before the protein leaves the ribosome whereas...
Hsp60 interferes after the protein has been fully synthesized. The Hsp70 is the best studied Hsp in ischemic stroke. Depending on its location, opposite effects of Hsp70 have been described. Intracellular Hsp70 can decrease the signaling of proinflammatory factors such as the transcription factor NFκB, MMPs and reactive oxygen species (ROS). Located in the extracellular matrix, Hsp70 binds to TLRs on macrophages, dendritic cells and microglia, and thereby activates the proinflammatory NFκB and its associated pathways. It can also elicit the immune response of CD4+ T cells and microglia, and thereby activates the proinflammatory NFκB. Located in the extracellular matrix, Hsp70 can be detected in neurons, microglia, astrocytes and endothelial cells. TNFα and IL-1β were downregulated after Hsp70 overexpression in experimental stroke. Increased intracellular Hsp70 protein expression appears to be cerebro protective in stroke studies of viral overexpression in neurons and glia, whereas Hsp70 knockouts worsen outcome. Additionally, exogenously delivered Hsp70 has a neuroprotective function. This is demonstrated by intravenous injection of Hsp70 in rat, reducing the cerebral infarction zone. Dynamin is a downregulated protein by Hsp70, which increases after experimental stroke. It transfers the death receptor Fas to the cell surface, inducing apoptosis after its ligands have bonded. A selective dynamin inhibitor also showed neuroprotective effects and may serve as a new therapeutic target. Taken together, it seems that Hsp70 is mainly protective in stroke though detrimental effects such as the activation of the immune system.

It is the Y-box binding protein (YB-1), respectively DNA-binding protein B (DbpB), which is a prototype of the conserved cold shock domain proteins. It binds single-stranded RNA or DNA via two ribonucleoprotein domains (RN-P1 and RN-P2) to prevent annealing upon the induction of cold shock, and thus affects multiple cellular functions. YB-1 takes part in a set of bacterial and sterile inflammatory processes. It is upregulated in proliferating microglia in an experimental ischemia model. The cold-inducible RNA-binding protein (CIRP) also belongs to the group of stress-responsive proteins with RNPs. When it is released from microglia after experimental ischemic brain injury, it fosters neuroinflammation via CIRP-NFκB-mediated TNFα expression. Moreover, in CIRP-deficient mice, the brain infarct volume, TNFα levels and activation of microglia are decreased. Therapeutic hypothermia is discussed to be neuroprotective after stroke. In experimental stroke research, hypothermia upregulates CIRP and Hsp70.1 and decreases TNFα and IL-6. To sum up, both CIRP and YB-1 appear to have damaging functions in stroke.

**Peroxiredoxins**

Peroxiredoxin is a redox-active cytosolic DAMP, which is neuroprotective within cells by eliminating ROS, but loses its antioxidant capacity once released. The oxidized peroxiredoxin 2 (PRDX2) is a set free from macrophages under inflammatory conditions and stimulates the production of TNFα. Peroxiredoxin family proteins (Prxs) like Prx-1, Prx-2, Prx-5 and Prx-6 are released from necrotic brain cells 12 h after stroke onset and induce the production of proinflammatory cytokines like IL-23 from macrophages through TLR2 and TLR4 binding. IL-23 induces IL-17-producing γδT cells and is responsible for delayed brain damage as neutrophils are recruited. Concordantly, the application of anti-IL-17 antibodies reduces infarct sizes and improves neurological outcome. Prx antibodies can reduce brain damage up to 12 h after ischemia. More than HMGB1, Prxs activate infiltrating macrophages. Only exogenous Prx-1, Prx-2 and Prx-4 seem to act as proinflammatory in the ischemic brain through TLR4/NFκB signaling whereas Prx-3, Prx-5 and Prx-6 have no relevant effect on the production of NO, TNFα, IL-6, iNOS and TLR4 expression in macrophages. In humans, low plasma levels of Prx-5 but high levels of Prx-1 during the first hours after stroke onset are found. Treatment with a gastrodin derivative, a constituent from the medicinal plant *Gastrodiae rhizoma*, reduced the post-ischemic expression of Prx-1, Prx-2 and Prx-4 after middle cerebral artery occlusion (MCAO) and the overall inflammatory response. However, there is also evidence that Prx-2 can have neuroprotective effects in stroke as it inhibits both the poly (ADP-ribose) polymerase 1 (PARP1) and the p53-Bax-mediated death pathway. Overall, peroxiredoxins mainly have damaging effects after stroke onset.

**Purines**

Extracellular nucleotides such as ATP serve as a multifunctional intercellular signaling system. Not only are they actively secreted through plasma membrane proteins such as pannexin and
Therapeutic Advances in Neurological Disorders 11

metabolism was prolonged. As a result, decreased particles conjugated with adenosine, so that its also in lymphocytes and neutrophils. In the first 20 min after ischemia, the ATP extracellular concentration rises. Simultaneously, the degradation of ATP by ectonucleotidases is initiated so extracellular ATP rises. Simultaneously, the degradation of ATP by ectonucleotidases is initiated so extracellular adenosine increases. This excitotoxicity returns to its basal level after about 4 h. ATP concentration increases due to various mechanisms, for example, a vesicular release from neurons, exocytosis from astrocytes and microglia, or through membrane channels from glial cells and pyramidal neurons. ATP itself aggravates cerebral damage after ischemic stroke as high ATP concentrations induce cell death. All P1 and P2 receptor subtypes are expressed in neurons and glial cells, but also in lymphocytes and neutrophils. Binding of the receptor P2X7 stimulates the inflammasome and enhances caspase-1 activity and the release of proinflammatory cytokines from innate immune cells. The receptor activation happens on K+ efflux through the cell membrane. The highest concentrations of the purinergic receptor P2X7 can be measured on activated microglia, which leads to IL-1β release. The P2Y2 receptor is upregulated due to a rising IL1-β concentration after the P2X7 receptor is stimulated on microglia and astrocytes. CD39-deficient mice, leading to less ATP metabolism, show larger infarct areas and more neutrophils and macrophages enter the CNS. Hyman and colleagues have shown that CD39 on endothelial cells and leukocytes regulates their influx in the cerebral infarct zone. The usage of a P2X7 antagonist or P2X7R blockade by Brilliant Blue G leads to a decrease in cerebral damage after ischemia in vivo. In contrast, Masuch and colleagues demonstrated a neuroprotective effect of microglia in organotypic hippocampal slice cultures, which is mediated by the P2X7 activation and the induction of TNFα. P2X7 activation also leads to alterations of the T-cell surface and can even cause T-cell death in the case of prolonged stimulation. In contrast to ATP, adenosine, the end product of CD39, is considered to be neuroprotective. Gaudin and colleagues created nanoparticles conjugated with adenosine, so that its metabolism was prolonged. As a result, decreased parenchymal damage after experimental cerebral ischemia was observed. Concerning CD39, pre-treatment with the small molecule inhibitor 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone (Mdivi-1) raises adenosine in a MCAO mouse model, consequently protecting against cerebral ischemia. CD39 level was also increased as well as the cAMP response element-binding protein (CREB), which regulates CD39 expression. In summary, purines are involved in the cellular reactions after ischemic stroke and it appears that ATP has a detrimental function whereas adenosine shows positive neuroprotective effects.

Other DAMPs in stroke
Apart from the discussed DAMPs, several more candidates have to be considered, including lipids and other proteins (S100A9; Mrp 8, Mrp9, CIRP, ASC specks). Controversial opinions exist on the exact functions of these molecules in the field of stroke (for a review see Shichita and colleagues). In primary microglial culture, exogenous S100B appears to induce the expression of IL-1β, TNFα and iNOS, and in vivo injections of S100B activate microglia. These effects can be suppressed by the addition of poly (ADP-ribose) polymerase 1 (PARP-1). Moreover, levels of hyaluronan, a large glycosaminoglycan in the extracellular matrix, are increased in patients with acute stroke. Concerning patients with intracerebral hemorrhagia, serum hyaluronan levels can be used for a prediction of the 3-month functional outcome. Cerebral hyaluronan expression is also induced by cortical ischemia, as shown in an experimental stroke mouse model. Other endogenous TLR ligands, such as fibronectin, defensin or heparin sulfate proteoglycan, also activate TLR2 and TLR4, and are potentially involved in the initiation of sterile inflammatory responses. Their role in stroke is still to be revealed. As a conclusion, various intracellular and also extracellular components might be involved as DAMPs in the inflammatory reactions after stroke, but until now their functions remain unclear.

DAMPs and microglia
Microglia are the resident immune cells of the cerebral nervous system and they are mainly responsible for the local immune surveillance. Overall, microglia is a heterogeneous population with a broad variety of functions and highly
plastic. Recently, a microglia-focused multicolor reporter mouse model monitored microglia dynamics in different states of health, disease and recovery. A self-renewing network with regional differences was described as being capable of reacting to different environmental challenges. Selected clonal expansion was observed in response to acute neurodegeneration as well as selected apoptosis in means of restoring homeostasis. Neuronal cell injury alters the local microglia from a ramified phenotype to a macrophage-like one.

Regarding brain ischemia, hypoxia affects local microglia, which changes either into a proinflammatory or anti-inflammatory phenotype characterized by different secreted mediators. There is no uniform response to injury as the relationship of microglia is complex. More precisely, a spatiotemporal relationship between microglia morphology and localization of ischemic injury is established. The activation of microglia is one of the first main responses to brain ischemia but continues for several weeks. In vitro stroke models it was shown that microglia can worsen neuronal damage. On the contrary, Szalay and colleagues elucidated these protective effects. In an experimental study the authors treated their animals with the colony-stimulating factor 1 receptor CSF1R antagonist PLX3397 for 21 days, which resulted in a 98% decrease of microglia. This selective elimination of microglia led to a 60% augmented neuronal death after MCAO in mice. Consequently, microglia are not yet completely understood as players in the concert of cellular reactions after ischemic stroke.

DAMPs interact with microglia and specific pathways are activated accounting for the polarization of microglia and their response to cell injury after stroke. One of the involved DAMPs is HMGB1. An autocrine loop includes the binding of glucocorticoids to microglia, which results in the release of the disulfide form of HMGB1 (dsHMGB1) and subsequent binding of dsHMGB1 to TLR2/4 as part of the priming process. Inescapable tail shocks (ISs) in rat lead to elevated levels of HMGB1, an upregulation of the transcription factor NFκB and its NLRP3 inflammasome in microglia. A second immune challenge results in a potentiated proinflammatory response of microglia with elevated levels of IL-1β. Here, it is again the disulfide form of HMGB1, which induces the priming process. Moreover, high concentrations of dsHMGB1 can be measured in the serum of patients with stroke. When it comes to future therapeutic targeting of HMGB1, inflachromene inhibits microglia activation, and thus the release of HMGB1 with a reduced proinflammatory response. As a result, HMGB1 is a main activator of microglia after ischemic stroke and its inhibition could possibly be a neuroprotective therapeutic option.

Hsps also interact with microglia in stroke. In the case of danger, Hsp70 associates with the Na+/H+ exchanger 1 (NHE1), Ca2+ streams into the cell, which activates both the Ca2+/calmodulin-dependent protein kinase II (CaMKII) and transforming growth factor β-activated kinase 1 (TAK1). IκB kinase β (IKKβ) initiates the degradation of IκB-α, and thus liberates NFκB resulting in a higher gene transcription of, for example, iNOS. [Figure 1(b)]. Whereas extracellularly located, Hsp activates microglia through TLRs, upregulating NFκB, hypoxia inducible factor 1 (HIF-1), interferon regulator factor 1 (IRF1) and single transducer and activator of transcription 3 (STAT3). This results in the release of proinflammatory cytokines such as IL-1β, IL-6, IL-12 and TNFα. Another player in the fields of microglia activation after stroke is Hsp72. It is the major cytosolic form of the 70 kDa family of Hsps and its overexpression in microglia is described to be cytoprotective as it interferes with the IKK-IκB-NFκB pathway. Doeppner and colleagues fused Hsp70 to the transactivator of transcription (TAT) domain of the human immunodeficiency virus to pass the blood–brain barrier. Intravenous infusion of TAT-Hsp70 reduced post-ischemic brain injury among others by diminished microglial activation. Notably, Hsp90 inhibits 70 kDa inducible Hsp70 synthesis. This is why treatment with an Hsp90 inhibitor such as geldanamycin prevents lipopolysaccharide (LPS)-induced BV2-microglial cell death through subsequent Hsp70 induction.

Regarding peroxiredoxins, Prx-1 is an antioxidant mainly expressed in microglia that diminishes microglial activation in proinflammatory processes. LPS is a randomly used inflammation (PAMP) activating microglia in several mammalian model systems. TLR agonists such as LPS upregulate Prx-1 via a ROS/p38 mitogen-activated protein kinase (MAPK)-dependent pathway and suppresses NFκB signaling, and thus nitric oxide (NO) production (Figure 2). The
Nox (membranous nicotinamide adenine dinucleotide phosphate (NADPH) oxidase)/ROS (reactive oxygen species)/JNK (c-jun N-terminal kinase) axis is also activated by LPS, and hence, NO as an inflammatory mediator rises. Prx-5 is upregulated by LPS and lowers intracellular ROS levels in microglia. Thereby, a balanced inflammatory response is generated.104 Furthermore, Prx-5 also reduces NFkB and MAPK activation in microglia after LPS application.105 When it comes to sterile inflammation after stroke, Prx-3 was significantly elevated from 3 days post ischemia in an ischemia/reperfusion stroke model (I/R). As a result, phagocytic processes in the subacute phase after stroke can be assumed.106 Prx-6 in microglia protects neurons against oxygen glucose deprivation and reoxygenation (OGD/R), showing a higher neuron viability.107 Exogenous
intraventricular Prx-3 treatment decreases microglia activation after experimental cerebral ischemia induction in gerbils.\textsuperscript{106} Furthermore, spinal cord injury in rat increases Prx-1 expression in astrocytes and microglia, which also enhances microglia proliferation after inflammation.\textsuperscript{108} Prx-1 was also induced in surrounding microglia after hemorrhagic stroke in rat.\textsuperscript{109} Interestingly, it appears that microglia is not the target of Prxs but infiltrating immune cells releasing IL-17 and IL-23.\textsuperscript{110} As a promising therapeutic approach, the natural compound obovatol suppresses Prx-2-mediated microglial activation in a NF\textkappa B-dependent manner.\textsuperscript{111}

ATP is a major modulator of microglial function with at least four different expressed ATP receptors (P2X4, P2X7, P2Y6, P2Y12) (Figure 3). P2X7 activation through ATP in cultured mouse primary microglia results in an increased release of IL-6, CCL2 and TNF\textalpha.\textsuperscript{112} Moreover, priming of cultured microglia with TLR isoform ligands such as LPS, a TLR4 ligand, lead to a release of IL-1\beta upon ATP application. The receptors TLR2, -3 and -4 are all found on microglia. The ATP-dependent release of IL-1\beta after pretreatment with TLR agonists can be blocked by a P2X7 antagonist A7410003 in primary cultures of microglia.\textsuperscript{113} Regarding the oxygen/glucose deprivation (OGD) model, an accepted cell culture stroke model, the ATP receptors P2X4 and P2X7 are upregulated on microglia, which accounts for cellular damage after OGD. Purinergic antagonists decreased cell injury under these conditions.\textsuperscript{114} The P2Y6 receptor on microglia is activated by uridine diphosphate (UDP) from damaged neurons, causing microglial phagocytosis, and thus limiting the inflammatory response after cell injury in \textit{in vitro} and \textit{in vivo} rat models.\textsuperscript{115} Phagocytosis is also enhanced by P2Y2/4 and P2Y12 receptors.\textsuperscript{116} In contrast to that, the P2Y12 receptor on microglia has a pro-inflammatory and chemotactic effect in brain ischemia models as inhibition improves neuron viability, which is interesting. As the common use of the antiplatelet agent clopidogrel targets P2Y12, an additional therapeutic side effect can be assumed.\textsuperscript{117} Moreover, P2Y-receptor-mediated Ca\textsuperscript{2+} signaling and migration of microglia, which are mainly dependent on P2Y1 and

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2}
\caption{Peroxiredoxin-associated pathways in microglia. Damaged-associated molecular patterns (DAMPs) such as peroxiredoxin family proteins Prx-1, -2 and -4 activate the Nox (membranous NADPH oxidase) / ROS (reactive oxygen species) / JNK (c-jun N-terminal kinase) axis and the concentrations of Nuclear-Factor \textkappa B (NF\textkappa B), mitogen-activated protein kinase (P38/MAPK) and reactive oxygen species (ROS) increase. Both Prx-1 and Prx-5 are upregulated and diminish the proinflammatory response by lowering ROS and NF\textkappa B signaling. Described pathways are best demonstrated by toll-like receptor (TLR) agonist lipopolysaccharide (LPS).}
\end{figure}
P2Y6 receptors, are altered by extracellular acidosis.118 On the other hand, 2',3'-cAMP released from damaged cells is metabolized by an extracellular pathway on microglia to 2'- and 3'-AMP, which is then metabolized to adenosine. Adenosine has a neuroprotective role if bound to its A1 receptor on microglia. Therefore, this 2',3'-cAMP-adenosine pathway functions as a limiting factor to the microglial response after cell injury.119 In LPS-stimulated microglia, a reduced number of A1 receptors can be observed whereby ATP limits its own activation potential.120

In summary, DAMPs play a major role in microglia activation and possess both neuroprotective and inflammatory functions.

**DAMPs and other cell types**

Besides microglia, other brain resident cells can also be activated through DAMPs. Concerning astrocytes, the expression of TLRs like TLR2 and -4 can be induced by DAMPs and other soluble factors, including interferon γ.121 In an oxygen-glucose deprivation/reoxygenation (OGD/R) model, the pathologic swelling of astrocytes can be mediated through TLR4, myeloid differentiation primary response gene 88 (MyD88) and NFκB.122 Further, it is known that astrocytes exhibit a PI3K/Akt-mediated upregulation of HMGB1 and IL-6 in the ischemic brain, which is crucial for their proangiogenic function.123 Moreover, a feedback loop between microglia and astrocytes exists. Following activation of microglia in primary cocultures, microglia-derived ATP recruits astrocytes, which in turn are a potential source of neurotoxic glutamate.124

Regarding endothelial cells, it has recently been shown that HMGB1 activates monocytes and endothelia via RAGE after stroke, resulting in atheroprogession, and thus vascular inflammation.125 It is
described that polarized peroxiredoxin 1 localizes to endothelial cells from ipsilateral brain microvessels 12 h after transient middle cerebral artery occlusion (tMCAO) induction in vivo, which might be involved in its neuroprotective effect on tight junction proteins. Additionally, it has been shown that in the early phase after ischemia, peroxiredoxin 1 is upregulated and owns neuro-protective functions whereas in the later stages the degradation of peroxiredoxin 1, mediated by the E3 ubiquitin ligase E6-associated protein (E6AP), results in neurovascular damage. When it comes to oligodendrocytes, an autocrine HMGB1-TLR2 axis is hypothesized. Following ischemia, released HMGB1 binds to TLR2, which results in the activation of protective signaling pathways. In this context, HMGB1 acts as an endogenous trophic factor for oligodendrocytes, supporting white matter integrity following ischemia.

In summary, the role of DAMPs on other cell types is diverse and further attempts are necessary to elucidate the exact involvement in means of stroke.

Conclusions and perspectives
A set of DAMPs were outlined in this review. Besides the neuroprotective effects of cold domain proteins or adenosine, proinflammatory reactions were described as induced by ATP or HMGB1. Therefore, DAMPs possess a wide variety of functions with context-specific effects dependent on cell type or intra- versus extracellular location. As released by necrotic cells after brain ischemia, they take part in the early reactions after stroke onset. Both the innate and the innate immune system are substantial players in the cellular concert after ischemia. The list of DAMPs can be extended by numerous other protein DAMPs, such as S100, serum amyloid A, histones and nonprotein DAMPs such as heparin sulfate, DNA or RNA. Their function is still to be further distinguished. Moreover, we shed light on the involvement of microglia, which play a major role in the acute innate immune reaction after brain ischemia. Microglia are affected by DAMPs but also secrete them actively. What is more, initial therapeutic strategies targeting DAMPs were discussed highlighting new methods in stroke therapy.

Funding
This work was supported by a grant from the Hermann and Lilly Schilling foundation.

Conflict of interest statement
The authors declare that there is no conflict of interest.

References
1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245–254.
2. Chamorro A, Dirnagl U, Urra X, et al. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol 2016; 15: 869–881.
3. Iadecola C and Anrather J. The immunology of stroke: from mechanisms to translation. Nature Med 2011; 17: 796–808.
4. Jin R, Liu L, Zhang S, et al. Role of inflammation and its mediators in acute ischemic stroke. J Cardiovasc Transl Res 2013; 6: 834–851.
5. Yilmaz G, Arumugam TV, Stokes KY, et al. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006; 113: 2105–2112.
6. Gelderblom M, Leypoldt F, Steinbach K, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009; 40: 1849–1857.
7. Planas AM, Gorina R and Chamorro A. Signalling pathways mediating inflammatory responses in brain ischaemia. Biochem Soc Trans 2006; 34: 1267–1270.
8. Hu X, Leak RK, Shi Y, et al. Microglial and macrophage polarization-new prospects for brain repair. Nat Rev Neurol 2015; 11: 56–64.
9. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991–1045.
10. Huang J, Xie Y, Sun X, et al. DAMPs, ageing, and cancer: the ‘DAMP Hypothesis.’ Ageing Res Rev 2015; 24: 3–16.
11. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1–5.
12. van de Beek D, Wijdicks EF, Vermij FH, et al. Preventive antibiotics for infections in acute stroke: a systematic review and meta-analysis. Arch Neurol 2009; 66: 1076–1081.
13. Yu Y, Tang D and Kang R. Oxidative stress-mediated HMGB1 biology. Front Physiol 2015; 6: 93.
14. Andersson U and Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. *Annu Rev Immunol* 2011; 29: 139–162.

15. Lotze MT and Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. *Nat Rev Immunol* 2005; 5: 331–342.

16. Scaffidi P, Misteli T and Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature* 2002; 418: 191–195.

17. Qiu J, Yoshinura M, Wang Y, et al. Early release of HMGB-1 from neurons after the onset of brain ischemia. *J Cereb Blood Flow Metab* 2008; 28: 927–938.

18. Venereau E, Schiraldi M, Uguccioni M, et al. HMGB1 and leukocyte migration during trauma and sterile inflammation. *Mol Immunol* 2013; 55: 76–82.

19. Lorenzen I, Mullen L, Bekeschus S, et al. Redox regulation of inflammatory processes is enzymatically controlled. *Oxid Med Cell Longev* 2017; 2017: 8459402.

20. Yang H, Lundback P, Ottosson L, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). *Mol Med* 2012; 18: 250–259.

21. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. *Proc Natl Acad Sci U S A* 2010; 107: 11942–11947.

22. Frank MG, Weber MD, Fonken LK, et al. The redox state of the alarmin HMGB1 is a pivotal factor in neuroinflammatory and microglial priming: a role for the NLRR3 inflammasome. *Brain Behav Immun* 2016; 55: 215–224.

23. Goldstein RS, Gallowitsch-Puerta M, Yang L, et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. *Shock* 2006; 25: 571–574.

24. Huang JM, Hu J, Chen N, et al. Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke. *J Crit Care* 2013; 28: 792–797.

25. Schulze J, Zierath D, Tanzi P, et al. Severe stroke induces long-lasting alterations of high-mobility group box 1. *Stroke* 2013; 44: 246–248.

26. Sapoñikova N, Kartvelishvili T, Asatiani N, et al. Correlation between MMP-9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome. *Biochim Biophys Acta* 2014; 1842: 1379–1384.

27. Tian X, Liu C, Shu Z, et al. Therapeutic targeting of HMGB1 in stroke. *Curr Drug Deliv* 2017; 14: 785–790. DOI: 10.2174/15672018136616080811933

28. Semino C, Angelini G, Poggi A, et al. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. *Blood* 2005; 106: 609–616.

29. Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. *EMBO J* 2003; 22: 5551–5560.

30. Dumitriu IE, Bianchi ME, Bacci M, et al. The secretion of HMGB1 is required for the migration of maturing dendritic cells. *J Leukoc Biol* 2007; 81: 84–91.

31. Richard SA, Sackey M, Su Z, et al. Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke. *Biosci Rep* 2017; 37: pii: BSR20171104.

32. Liesz A, Dalpke A, Mracsko E, et al. DAMP signaling is a key pathway inducing immune modulation after brain injury. *T Biomed* 2015; 35: 583–598.

33. Sundberg E, Fasth AE, Palmblad K, et al. High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. *Immunobiology* 2009; 214: 303–309.

34. Kim JB, Sig Choi J, Yu YM, et al. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. *J Neurosci* 2006; 26: 6413–6421.

35. Halder SK and Ueda H. Amlexanox inhibits cerebral ischemia-induced delayed astrocytic high-mobility group box 1 release and subsequent brain damage. *J Pharmacol Exp Ther*. Epub ahead of print 12 January 2018. DOI: 10.1124/jpet.117.245340.

36. Kituchi K, Tancharoen S, Ito T, et al. Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. *Int J Mol Sci* 2013; 14: 18899–18924.

37. Gong G, Xiang L, Yuan L, et al. Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/ reperfusion-induced inflammation, oxidative...
stress, and apoptosis in rats. PLoS One 2014; 9: e89450. DOI: 10.1371/journal.pone.0089450.

38. Tang SC, Wang YC, Li YI, et al. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol 2013; 33: 585–594.

39. Tang SC, Arumugam TV, Xu X, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007; 104: 13798–13803.

40. Alberts B. Molecular biology of the cell. New York, NY: Garland Science Taylor & Francis, 2008.

41. Sharp FR, Zhan X and Liu DZ. Heat shock couple with activities far beyond the cold. J Mol Med (Berl) 2014; 92: 207–216.

42. Li CY, Zhan X, Zhang Z, et al. Role of cold shock domain proteins in inflammatory diseases. J Mol Med (Berl) 2014; 92: 207–216.

43. Zhan X, Ander BP, Liao IH, et al. Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats. Stroke 2010; 41: 538–543.

44. Kim JY, Kim N, Zheng Z, et al. 70-kDa heat shock protein downregulates dynamin in experimental stroke: a new therapeutic target? Stroke 2016; 47: 2103–2111.

45. Kim JY, Kim N, Zheng Z, et al. 70-kDa heat shock protein downregulates dynamin in experimental stroke: a new therapeutic target? Stroke 2016; 47: 2103–2111.

46. Lindquist JA, Brandt S, Bernhardt A, et al. The role of cold shock domain proteins in inflammatory diseases. J Mol Med (Berl) 2014; 92: 207–216.

47. Hanssen L, Alidousty C, Djudjaj S, et al. YB-1 is an early and central mediator of bacterial and sterile inflammation in vivo. J Immunol 2013; 191: 2604–2613.

48. Keilhoff G, Titze M, Esser T, et al. Constitutive and functional expression of YB-1 in microglial cells. Neuroscience 2015; 301: 439–453.

49. Zhan X, Buhrer C and Wellmann S. Cold-inducible proteins CIRP and RBM3, a unique couple with activities far beyond the cold. Cell Mol Life Sci 2016; 73: 3839–3859.
to determine time-of-onset of acute cerebral infarction. Sci Rep 2016; 6: 38300.

63. Mao XN, Zhou HJ, Yang XJ, et al. Neuroprotective effect of a novel gastrodin derivative against ischemic brain injury: involvement of peroxiredoxin and TLR4 signaling inhibition. Oncotarget 2017; 8: 90979–90995.

64. Leak RK, Zhang L, Luo Y, et al. Peroxiredoxin 2 battles poly(ADP-ribose) polymerase 1- and p53-dependent prodeath pathways after ischemic injury. Stroke 2013; 44: 1124–1134.

65. Hechler B and Gachet C. Purinergic receptors in thrombosis and inflammation. Arterioscler Thromb Vasc Biol 2015; 35: 2307–2315.

66. Pedata F, Dettori I, Coppi E, et al. Purinergic signalling in brain ischemia. Neuropharmacology 2016; 104: 105–130.

67. Cisneros-Mejorado A, Perez-Samartin A, Gottlieb M, et al. ATP signaling in brain: release, excitotoxicity and potential therapeutic targets. Cell Mol Neurobiol 2015; 35: 1–6.

68. Beamer E, Goloncser F, Horvath G, et al. Purinergic mechanisms in neuroinflammation: an update from molecules to behavior. Neuropharmacology 2016; 104: 94–104.

69. Kanthi YM, Sutton NR and Pinsky DJ. CD39: Interface between vascular thrombosis and inflammation. Curr Atheroscler Rep 2014; 16: 425.

70. Hyman MC, Petrovic-Djergovic D, Visovatti SH, et al. Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 2009; 119: 1136–1149.

71. Arbeloa J, Perez-Samartin A, Gottlieb M, et al. P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol Dis 2012; 45: 954–961.

72. Burnstock G. Purinergic signalling: therapeutic developments. Front Pharmacol 2017; 8: 661.

73. Cisneros-Mejorado A, Gottlieb M, Cavaliere F, et al. Blockade of P2X7 receptors or pannexin-1 channels similarly attenuates posts ischemic damage. J Cereb Blood Flow Metab 2015; 35: 843–850.

74. Masuch A, Shieh CH, van Rooijen N, et al. Mechanism of microglia neuroprotection: involvement of P2X7, TNFalpha, and valproic acid. Glia 2016; 64: 76–89.

75. Rissiek B, Haag F, Boyer O, et al. P2X7 on mouse T cells: one channel, many functions. Front Immunol 2015; 6: 204.

76. Gaudin A, Yemisci M, Eroglu H, et al. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nat Nanotechnol 2014; 9: 1054–1062.

77. Cui M, Ding H, Chen F, et al. Mdivi-1 Protects against ischemic brain injury via elevating extracellular adenosine in a CAMP/CREB-CD39-dependent manner. Mol Neurobiol 2016; 53: 240–253.

78. Shichita T, Ito M and Yoshimura A. Posts ischemic inflammation regulates neural damage and protection. Front Cell Neurosci 2014; 8: 319.

79. Xu J, Wang H, Won SJ, et al. Microglial activation induced by the alarmin S100B is regulated by poly(ADP-ribose) polymerase-1. Glia 2016; 64: 1869–1878.

80. Tang SC, Yeh SJ, Tsai LK, et al. Association between plasma levels of hyaluronic acid and functional outcome in acute stroke patients. J Neuroinflammation 2014; 11: 101.

81. Lindwall C, Olsson M, Osman AM, et al. Selective expression of hyaluronan and receptor for hyaluronan mediated motility (Rhamm) in the adult mouse subventricular zone and rostral migratory stream and in ischemic cortex. Brain Res 2013; 1503: 62–77.

82. Arumugam TV, Okun E, Tang SC, et al. Toll-like receptors in ischemia-reperfusion injury. Shock 2009; 32: 4–16.

83. Nayak D, Roth TL and McGavern DB. Microglia development and function. Annu Rev Immunol 2014; 32: 367–402.

84. Morrison HW and Filosa JA. A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion. J Neuroinflammation 2013; 10: 4.

85. Boche D, Perry VH and Nicoll JA. Review: activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol 2013; 39: 3–18.

86. Tay TL, Mai D, Dautzenberg J, et al. A new fate mapping system reveals context-dependent random or clonal expansion of microglia. Nat Neurosci 2017; 20: 793–803.

87. Biber K, Owens T and Boddeke E. What is microglia neurotoxicity (Not)? Glia 2014; 62: 841–854.

88. Lee Y, Lee SR, Choi SS, et al. Therapeutically targeting neuroinflammation and microglia after acute ischemic stroke. Biomed Res Int 2014; 2014: 297241.
89. Aguzzi A, Barres BA and Bennett ML. Microglia: scapegoat, saboteur, or something else? *Science* 2013; 339: 156–161.

90. Huang WC, Qiao Y, Xu L, et al. Direct protection of cultured neurons from ischemia-like injury by minocycline. *Anat Cell Biol* 2010; 43: 325–331.

91. Szalay G, Martinez B, Lenart N, et al. Microglia protect against brain injury and their selective elimination dysregulates neuronal network activity after stroke. *Nat Commun* 2016; 7: 11499.

92. Frank MG, Weber MD, Watkins LR, et al. Stress sounds the alarmin: The role of the danger-associated molecular pattern HMGB1 in stress-induced neuroinflammatory priming. *Brain Behav Immun* 2015; 48: 1–7.

93. Weber MD, Frank MG, Tracey KJ, et al. Stress induces the danger-associated molecular pattern HMGB-1 in the hippocampus of male Sprague Dawley rats: a priming stimulus of microglia and the NLRP3 inflammasome. *Journal Neurosci* 2015; 35: 316–324.

94. Weber MD, Frank MG, Sobesky JL, et al. Blocking toll-like receptor 2 and 4 signaling during a stressor prevents stress-induced priming of neuroinflammatory responses to a subsequent immune challenge. *Brain Behav Immun* 2013; 32: 112–121.

95. Lee S, Nam Y, Koo JY, et al. A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation. *Nat Chem Biol* 2014; 10: 1055–1060.

96. Martinon F, Mayor A and Tschopp J. The inflammasomes: guardians of the body. *Annu Rev Immunol* 2009; 27: 229–265.

97. Huang C, Lu X, Wang J, et al. Inhibition of endogenous heat shock protein 70 attenuates inducible nitric oxide synthase induction via disruption of heat shock protein 70/Na+(+)/H+(+) exchanger 1-Ca(2+)-calcium-calmodulin-dependent protein kinase II transforming growth factor-β-activated kinase 1-nuclear factor-kappaB signals in BV-2 microglia. *J Neurosci Res* 2015; 93: 1192–1202.

98. Kim N, Kim JY and Yenari MA. Anti-inflammatory properties and pharmacological induction of Hsp70 after brain injury. *Inflammopharmacology* 2012; 20: 177–185.

99. Sheppard PW, Sun X, Khammash M, et al. Overexpression of heat shock protein 72 attenuates NF-kappaB activation using a combination of regulatory mechanisms in microglia. *PLoS Comput Biol* 2014; 10: e1003471. DOI: 10.1371/journal.pcbi.1003471.

100. Zheng Z, Kim JY, Ma H, et al. Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. *J Cereb Blood Flow Metab* 2008; 28: 53–63.

101. Kacimi R and Yenari MA. Pharmacologic heat shock protein 70 induction confers cytoprotection against inflammation in gliovascular cells. *Glia* 2015; 63: 1200–1212.

102. Jin MH, Lee YH, Kim JM, et al. Characterization of neural cell types expressing peroxiredoxins in mouse brain. *Neurosci Lett* 2005; 381: 252–257.

103. Kim SU, Park YH, Min JS, et al. Peroxiredoxin I is a ROS/p38 MAPK-dependent inducible antioxidant that regulates NF-kappaB-mediated iNOS induction and microglial activation. *J Neuroimmunol* 2013; 259: 26–36.

104. Sun HN, Kim SU, Huang SM, et al. Microglial peroxiredoxin V acts as an inducible anti-inflammatory antioxidant through cooperation with redox signaling cascades. *J Neurochem* 2010; 114: 39–50.

105. Park J, Choi H, Kim B, et al. Peroxiredoxin 5 (Prx5) decreases LPS-induced microglial activation through regulation of Ca(2+)/calcinerin-Drp1-dependent mitochondrial fission. *Free Radic Biol Med* 2016; 99: 392–404.

106. Hwang IK, Yoo KY, Kim DW, et al. Changes in the expression of mitochondrial peroxiredoxin and thioredoxin in neurons and glia and their protective effects in experimental cerebral ischemic damage. *Free Radic Biol Med* 2010; 48: 1242–1251.

107. Tan L, Zhao Y, Jiang B, et al. [Knockdown of PRDX6 in microglia reduces neuron viability after OGD/R injury]. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi* 2016; 32: 1014–1020.

108. Huang S, Liu X, Zhang J, et al. Expression of peroxiredoxin 1 after traumatic spinal cord injury in rats. *Cell Mol Neurobiol* 2015; 35: 1217–1226.

109. Nakaso K, Kitayama M, Mizuta E, et al. Co-induction of heme oxygenase-1 and peroxiredoxin I in astrocytes and microglia around hemorrhagic region in the rat brain. *Neurosci Lett* 2000; 293: 49–52.

110. García-Bonilla L and Iadecola C. Peroxiredoxin sets the brain on fire after stroke. *Nat Med* 2012; 18: 858–859.
111. Suk K and Ock J. Chemical genetics of neuroinflammation: natural and synthetic compounds as microglial inhibitors. *Inflammopharmacology* 2012; 20: 151–158.

112. Shieh CH, Heinrich A, Serchov T, et al. P2X7-dependent, but differentially regulated release of IL-6, CCL2, and TNF-alpha in cultured mouse microglia. *Glia* 2014; 62: 592–607.

113. Faciù L, Barbierato M, Marinelli C, et al. Toll-like receptors 2, -3 and -4 prime microglia but not astrocytes across central nervous system regions for ATP-dependent interleukin-1β release. *Sci Rep* 2014; 4: 6824.

114. Cavaliere F, Dinkel K and Reymann K. Microglia response and P2 receptor participation in oxygen/glucose deprivation-induced cortical damage. *Neuroscience* 2005; 136: 615–623.

115. Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. *Nature* 2007; 446: 1091–1095.

116. Castellano B, Bosch-Queralt M, Almolda B, et al. Purine signaling and microglial wrapping. *Adv Exp Med Biol* 2016; 949: 147–165.

117. Webster CM, Hokari M, McManus A, et al. Microglial P2Y12 deficiency/inhibition protects against brain ischemia. *PLoS One* 2013; 8: e70927. DOI: 10.1371/journal.pone.0070927.

118. Langfelder A, Okonji E, Deca D, et al. Extracellular acidosis impairs P2Y receptor-mediated Ca(2+) signalling and migration of microglia. *Cell Calcium* 2015; 57: 247–256.

119. Verrier JD, Exo JL, Jackson TC, et al. Expression of the 2’,3’-cAMP-adenosine pathway in astrocytes and microglia. *J Neurochem* 2011; 118: 979–987.

120. Luongo L, Guida F, Imperatore R, et al. The A1 adenosine receptor as a new player in microglia physiology. *Glia* 2014; 62: 122–132.

121. Sofroniew MV. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. *Neuroscientist* 2014; 20: 160–172.

122. Sun L, Li M, Ma X, et al. Inhibition of HMGB1 reduces rat spinal cord astrocytic swelling and AQP4 expression after oxygen-glucose deprivation and reoxygenation via TLR4 and NF-kappaB signaling in an IL-6-dependent manner. *J Neuroinflammation* 2017; 14: 231.

123. Chen JY, Yu Y, Yuan Y, et al. Enriched housing promotes post-stroke functional recovery through astrocytic HMGB1-IL-6-mediated angiogenesis. *Cell Death Discov* 2017; 3: 17054.

124. Pascual O, Ben Achour S, Rostaing P, et al. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. *Proc Natl Acad Sci U S A* 2012; 109: E197–E205.

125. Roth S, Singh V, Tiedt S, et al. Brain-released alarmins and stress response synergize in accelerating atherosclerosis progression after stroke. *Sci Transl Med* 2018; 10: pii: eaa01313.

126. Ye WF, Tao RR, Jiang Q, et al. Peroxiredoxin 1 participates in ischemia-triggered endothelial polarization. *CNS Neurosci Ther* 2014; 20: 791–793.

127. Tao RR, Wang H, Hong LJ, et al. Nitrosative stress induces peroxiredoxin 1 ubiquitination during ischemic insult via E6AP activation in endothelial cells both in vitro and in vivo. *Antioxid Redox Signal* 2014; 21: 1–16.

128. Choi JY and Kim BG. Toll-like receptor 2: a novel therapeutic target for ischemic white matter injury and oligodendrocyte death. *Exp Neurobiol* 2017; 26: 186–194.

129. Choi JY, Cui Y, Chowdhury ST, et al. High-mobility group box-1 as an autocrine trophic factor in white matter stroke. *Proc Natl Acad Sci U S A* 2017; 114: E4987–E4995.